Promotion of Hair Growth in Alopecia Areata by Topical Treatment of HDAC Inhibitors
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
Studysummary This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata. Our plain-language summary of this paper — not a Tressless recommendation.
The study investigated the use of HDAC inhibitors, specifically Vorinostat and Entinostat, for treating alopecia areata (AA), an autoimmune hair loss condition. Vorinostat, an FDA-approved HDAC1/3 inhibitor, was predicted to target over 50% of the dysregulated pathways in AA. Topical application of Vorinostat (2% in DMSO) on C3H/HeJ mice with AA induced significant hair regrowth within 5 weeks. Vorinostat also inhibited IFNg production and decreased proliferation of activated immune cells in vitro. Entinostat (2%) was found to be more effective than Vorinostat in reversing AA in mice. ATAC-seq analysis of T cells from AA-affected and non-alopecic mice revealed differences in transcription factor binding sites, suggesting epigenetic modulation. The findings supported the potential of HDAC inhibitors as a novel therapeutic approach for AA.
